Multilayer solid phase immunoassay support and method of use

• US 5,120,662 A
• Filed: 06/04/1990
• Issued: 06/09/1992
• Est. Priority Date: 05/09/1989
• Status: Expired due to Fees

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Stephens, John E., Defreese, James D., Vallaris, David S., Daluga, Cynthia K., Stojak, Joseph J. II, Braun, Brian P., Durley, deceased, Benton A., Schulze, Werner, Merkh, Carl W., Chan, Emerson W., Kapsalis, Andreas A., Knigge, Kevin M., Robey, William G.
• Primary Examiner(s): Nucker, Christine
• Assistant Examiner(s): PRESTON, DAVID
• Application Number:
  US07/532,489
• Time in Patent Office: 736 Days
• Field of Search: 435/4, 435/7, 435/7.92, 435/7.91, 435/970, 435/7.93, 435/7.94, 435/7.95, 435/291, 436/524, 436/518, 436/531, 436/811, 436/820, 436/824, 436/530, 436/501, 436/809, 436/808
• US Class Current: 436/530
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/56988 HIV or HTLV
• CPC Class Codes: Y10S 436/808 Automated or kit
• CPC Class Codes: Y10S 436/809 Multifield plates or multicontainer arrays

Abstract

An immunoassay which is capable of simultaneously detecting any desired number of antigens of one infectious agent, or combinations of antigens of several infectious agents, or any desired number of immunoglobulins of one infectious agent, or combinations of immunoglobulins of several infectious agents on a single solid support. A test sample is contacted with a solid support on which one or more antigens are immobilized as discrete test sites. Antigen-antibody complexes are formed and detected on the solid support.

Claims

1. An immunoassay to simultaneously detect the presence or amount of more than one antibody which may be present in a test sample, said assay comprising:

a. contacting a test sample of a species with a porous solid support backed by inert plastic on which said porous solid support more than one antigen is immobilized each on its own discrete test site which is isolated by a surrounding moat created by a depression which extends substantially through the porous solid support and which said porous solid support was treated with a blocking reagent after said antigens were immobilized, for a time and under conditions sufficient to form antigen-antibody complexes;

b. contacting said antigen-antibody complexes with a conjugated signal generating system comprising an anti-species antibody which anti-species antibody binds to the antigen-antibody complexes and which antibody is conjugated to a detectable label which is capable of yielding a quantitatively measurable signal correlated to the signal of a normal negative test sample to indicate antibody positive or antibody negative for the test sample; and

c. detecting the presence of said antigen-antibody complexes on said porous solid support by measuring the generated signal.

2. The immunoassay of claim 1 wherein the porous solid support is nitrocellulose.

3. The immunoassay of claim 1 wherein the discrete test site is an immunodot blot.

4. The immunoassay of claim 1 wherein the antibody detected is selected from the group consisting of anti-HIV-1 antibody, anti-HIV-2 antibody and anti-HCV antibody.

5. The immunoassay of claim 1 wherein the antibody detected is anti-HIV-1 antibody.

6. The immunoassay of claim 1 wherein the antibody detected is anti-HIV-2 antibody.

7. The immunoassay of claim 1 wherein the antibody detected is anti-HCV antibody.

8. The immunoassay of claim 1 wherein the solid support is contacted with a blocking reagent prior to contacting the solid support with the test sample.

9. The immunoassay of claim 1 wherein said label is selected from the group consisting of an enzyme, a luminescent label and a chemiluminescent label.

10. The immunoassay of claim 1 wherein said signal generating system is a biotin-anti-biotin amplifying system.

11. An immunoassay to simultaneously detect the presence or amount of more than one antigen which may be present in a test sample, said assay comprising:

a. contacting a test sample with a porous solid support backed by inert plastic on which said porous solid support more than one antibody is immobilized each on its own discrete test site which is isolated by a surrounding moat created by a depression which extends substantially through the porous solid support and which said porous solid support was treated with a blocking reagent after said antigens were immobilized, for a time and under conditions sufficient to form antigen-antibody complexes;

b. contacting said antigen-antibody complexes with a conjugated signal generating system comprising at least one anti-antigen antibody which antibody binds to the antigen-antibody complexes and which antibody is conjugated to a detectable label which is capable of yielding a quantitatively measurable signal correlated to the signal of a normal negative test sample to indicate antigen positive or antigen negative for the test sample; and

c. detecting the presence of said antigen-antibody complexes on said porous solid support by measuring the generated signal.

12. The immunoassay of claim 11 wherein the porous solid support is nitrocellulose.

13. The immunoassay of claim 11 wherein the discrete test site is an immunodot blot.

14. The immunoassay of claim 11 wherein the antigen detected is selected from the group consisting of HIV-1, HIV-2 and HCV.

15. The immunoassay of claim 11 wherein the antigen detected is HIV-1.

16. The immunoassay of claim 11 wherein the antigen detected is HIV-2.

17. The immunoassay of claim 11 wherein the antigen detected is HCV.

18. The immunoassay of claim 11 wherein the solid support is contacted with a blocking reagent prior to contacting the solid support with the test sample.

19. The immunoassay of claim 11 wherein said label is selected from the group consisting of an enzyme, a luminescent label and a chemiluminescent label.

20. The immunoassay of claim 11 wherein said signal generating system is a biotin-anti-biotin amplifying system.